Governments around the world have, in recent years in particular, made significant investments in health research - investments that bring potential benefits to the health of people worldwide and that play an important role in building strong scientific cultures and knowledge economies. The majority of this health research investment has been made into academia. However, there exists a significant gap in translating the resulting academic discoveries into commercially-viable investment opportunities for the private sector. And as the costs and risks associated with bringing new drugs or other therapeutic products to market become greater and greater, the various players (from government, to academic institutions and granting agencies, to translational research organizations, foundations and industry) must find new avenues to come together to fill the gaps in the development continuum and effectively de-risk early-stage technologies.
Category
Hybrid Groups: Bridging the Gap Between Industry and Academia
Year
2013
Summary
